Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.15B
Close$
$31.94
12.4% downside
Current Fair Value
12.4% downsideOvervalued by 12.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.15 Billion |
|---|---|
| Enterprise Value | $33.87 Billion |
| Dividend Yield | $0.48 (1.27%) |
| Earnings per Share | $4.7 |
| Beta | 0.34 |
| Outstanding Shares | 896,225,429 |
Return
| Return on Equity | 36.22% |
|---|---|
| Return on Assets | 35.03% |
| Return on Invested Capital | 40.09% |
Valuation & Multiples
| P/E Ratio | 7.82 |
|---|---|
| PEG | 6.46 |
| Price to Sales | 9.12 |
| Price to Book Ratio | 4.05 |
| Enterprise Value to Revenue | 7.66 |
| Enterprise Value to EBIT | 9.87 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$434.47 M
Average shareholder expectationNext Earnings Call
Expected Date
October 23, 2026
EPS Estimate
$0.15
Average shareholder expectationRevenue Estimate
$466.01 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
1,023 employees
CEO: Yanli Liu Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and dev...